Profile
Michael Cassano is Manager of Information Technology for Orasi Medical, Inc. Previously, he worked at John Wiley & Sons, Inc. Mr. Cassano received a BS degree in Computer Science from the Institute of Technology at the University of Minnesota and an MBA from the Carlson School of Management at the University of Minnesota in 2007.
Former positions of Michael Cassano
| Companies | Position | End |
|---|---|---|
Orasi Medical, Inc.
 Orasi Medical, Inc. Medical/Nursing ServicesHealth Services Orasi Medical, Inc. is a privately held, early stage medical device company engaged in the development and commercialization of technology to diagnose and monitor neurological diseases. They have developed a painless, non-invasive test that takes less than ten (10) minutes to administer and, based on the results of its current research, is more accurate than current clinical practice. Initially, its aim is to develop the first FDA cleared test for the diagnosis of Alzheimer's disease. In addition, they are developing products for pharmaceutical companies to measure treatment effect and reduce the cost of clinical drug trials for neurological diseases. Ultimately, its long-term goal is to set the standard of care for diagnosis and monitoring of major neurological diseases such as Alzheimer's disease, multiple sclerosis, Parkinson's, autism, depression and attention deficit hyperactivity disorder (ADHD). | Chief Tech/Sci/R&D Officer | 2012-08-17 |
| JOHN WILEY & SONS, INC. | Corporate Officer/Principal | - |
Training of Michael Cassano
| University of Minnesota | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| JOHN WILEY & SONS, INC. | Consumer Services |
| Private companies | 1 |
|---|---|
Orasi Medical, Inc.
Orasi Medical, Inc. Medical/Nursing ServicesHealth Services Orasi Medical, Inc. is a privately held, early stage medical device company engaged in the development and commercialization of technology to diagnose and monitor neurological diseases. They have developed a painless, non-invasive test that takes less than ten (10) minutes to administer and, based on the results of its current research, is more accurate than current clinical practice. Initially, its aim is to develop the first FDA cleared test for the diagnosis of Alzheimer's disease. In addition, they are developing products for pharmaceutical companies to measure treatment effect and reduce the cost of clinical drug trials for neurological diseases. Ultimately, its long-term goal is to set the standard of care for diagnosis and monitoring of major neurological diseases such as Alzheimer's disease, multiple sclerosis, Parkinson's, autism, depression and attention deficit hyperactivity disorder (ADHD). | Health Services |
- Stock Market
- Insiders
- Michael Cassano
